Prodrug Strategy for PSMA-Targeted Delivery of TGX-221 to Prostate Cancer Cells
详细信息 查看全文
- 作者：Yunqi Zhao ; Shaofeng Duan ; Xing Zeng ; Chunjing Liu ; Neal M. Davies ; Benyi Li ; M. Laird Forrest
- 刊名：Molecular Pharmaceutics
- 出版年：2012
- 出版时间：June 4, 2012
- 年：2012
- 卷：9
- 期：6
- 页码：1705-1716
- 全文大小：421K
- 年卷期：v.9,no.6(June 4, 2012)
- ISSN：1543-8392
文摘
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110尾 catalytic subunit. Recent studies showed that TGX-221 has antiproliferative activity against PTEN-deficient tumor cell lines including prostate cancers. The objective of this study was to develop an encapsulation system for parenterally delivering TGX-221 to the target tissue through a prostate-specific membrane aptamer (PSMAa10) with little or no side effects. In this study, PEG-PCL micelles were formulated to encapsulate the drug, and a prodrug strategy was pursued to improve the stability of the carrier system. Fluorescence imaging studies demonstrated that the cellular uptake of both drug and nanoparticles was significantly improved by targeted micelles in a PSMA positive cell line. The area under the plasma concentration time curve of the micelle formulation in nude mice was 2.27-fold greater than that of the naked drug, and the drug clearance rate was 6.16-fold slower. These findings suggest a novel formulation approach for improving site-specific drug delivery of a molecular-targeted prostate cancer treatment.